Cas:201481-37-0 Fmoc-Allo-Thr(tBu)-OH manufacturer & supplier

Chemical Name:Fmoc-Allo-Thr(tBu)-OH

CAS.NO:201481-37-0

Synonyms:(2S,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid;AmbotzFAA1655;L-Allothreonine, O-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-O-(2-methyl-2-propanyl)-L-allothreonine;Fmoc-Allo-Thr(tBu)-OH

Molecular Formula:C₂₃H₂₇NO₅

Molecular Weight:397.464

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:581.7±50.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.569

PSA:84.86000

Exact Mass:397.188934

LogP:5.45

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2S,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Fmoc-Allo-Thr(tBu)-OH physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-O-(2-methyl-2-propanyl)-L-allothreonine Use and application,N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-O-(2-methyl-2-propanyl)-L-allothreonine technical grade,usp/ep/jp grade.

Related News: In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. Fmoc-Allo-Thr(tBu)-OH manufacturer Under the strict supervision of environmental protection, it has helped the API industry to continuously optimize its product structure, realize industrial upgrading, and transition to the development of high-end APIs. Fmoc-Allo-Thr(tBu)-OH supplier In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. Fmoc-Allo-Thr(tBu)-OH vendor Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients. Fmoc-Allo-Thr(tBu)-OH factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.